Shares of Omnicell Inc. (NASDAQ:OMCL) dropped 2.6% on Thursday . The stock traded as low as $35.81 and last traded at $35.83, with a volume of 62,522 shares traded. The stock had previously closed at $36.77.

OMCL has been the topic of several research analyst reports. FBR & Co boosted their target price on shares of Omnicell from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, July 7th. Zacks Investment Research upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Finally, Topeka Capital Markets decreased their price objective on shares of Omnicell from $38.00 to $37.00 and set a “buy” rating for the company in a research note on Monday, March 21st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $37.25.

The stock’s 50-day moving average is $34.03 and its 200-day moving average is $29.88. The stock has a market capitalization of $1.29 billion and a PE ratio of 53.95.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, April 28th. The company reported $0.35 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.09. During the same period last year, the business earned $0.29 EPS. The firm earned $171 million during the quarter, compared to analyst estimates of $167.18 million. The firm’s revenue was up 47.1% compared to the same quarter last year. On average, equities analysts anticipate that Omnicell Inc. will post $1.56 earnings per share for the current year.

In other Omnicell news, Director Sara J. White sold 2,000 shares of the stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $31.76, for a total value of $63,520.00. Following the transaction, the director now directly owns 40,433 shares in the company, valued at $1,284,152.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jorge R. Taborga sold 23,827 shares of the stock in a transaction that occurred on Tuesday, April 26th. The shares were sold at an average price of $30.00, for a total transaction of $714,810.00. Following the completion of the transaction, the vice president now owns 52,667 shares in the company, valued at $1,580,010. The disclosure for this sale can be found here.

A number of institutional investors recently made changes to their positions in OMCL. Dimensional Fund Advisors LP raised its position in shares of Omnicell by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,641,466 shares of the company’s stock valued at $51,017,000 after buying an additional 51,729 shares in the last quarter. Paradigm Capital Management Inc. NY raised its position in shares of Omnicell by 32.4% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 412,600 shares of the company’s stock valued at $12,824,000 after buying an additional 100,900 shares in the last quarter. Century Capital Management LLC raised its position in shares of Omnicell by 1.5% in the fourth quarter. Century Capital Management LLC now owns 353,669 shares of the company’s stock valued at $10,992,000 after buying an additional 5,234 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Omnicell by 3.0% in the fourth quarter. Principal Financial Group Inc. now owns 241,880 shares of the company’s stock valued at $7,518,000 after buying an additional 6,979 shares in the last quarter. Finally, Edge Asset Management Inc. raised its position in shares of Omnicell by 41.0% in the fourth quarter. Edge Asset Management Inc. now owns 378,276 shares of the company’s stock valued at $11,757,000 after buying an additional 110,035 shares in the last quarter.

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.